EDUCATION CLINICAL REVIEW in clinical practice. However, when the serum protein concentration fluctuates, the total serum calcium level may vary accordingly, while ionised calcium remains stable.
Hypercalcaemia is a common finding in the setting of primary care, 1 as well as in emergency departments 2 and patients admitted to hospital.
3 Primary hyperparathyroidism and malignancy are the two most common causes of increased serum calcium levels, together accounting for about 90% of all cases. 4 This review aims to give an overview of the diagnosis and clinical management of hypercalcaemia for non-specialist clinicians and health professionals.
What is the definition of hypercalcaemia?
Hypercalcaemia is diagnosed when the concentration of serum calcium is 2 standard deviations above the mean of values found in people with normal calcium levels, in at least two samples at least one week apart over a period of three months. The serum concentration of total calcium in adults usually ranges between 2.15 and 2.60 mmol/L (8.6-10.4 mg/dL; 4.3-5.2 mEq/L). About 45% of calcium in blood is bound to plasma proteins, particularly albumin, and approximately 10% is bound to anions such as phosphate and citrate; free or ionised calcium (normal values 1.17-1.33 mmol/L) represents about 45% of total calcium. Although the ionised fraction of calcium is the one readily available for activating cellular processes, measurement of total serum calcium is mostly requested THE BOTTOM LINE • Primary hyperparathyroidism and malignancy are the two most common causes of increased serum calcium levels
• The diagnosis of hypercalcaemia is made when the corrected serum calcium concentration is 2 standard deviations above the mean of values found in people with normal calcium levels, in at least two samples at least one week apart over a period of three months
• The presence of high or not adequately suppressed serum parathyroid hormone levels should point the diagnosis towards hypercalcaemia of parathyroid origin
• Mild hypercalcaemia is usually caused by primary hyperparathyroidism, the treatment for which is typically surgery; those aged 50 or more with serum calcium levels <0.25 mmol/L above the upper limit of normal and without end organ damage may be followed up conservatively. Treatment with a calcimimetic agent, cinacalcet, is an option in selected cases
• Severe hypercalcaemia requires admission to hospital and treatment with aggressive intravenous hydration and bisphosphonates along with treatment of the underlying disease SOURCES AND SELECTION CRITERIA We carried out a search through Medline and PubMed of articles published from 1990 to 2015 using the terms "mild hypercalcaemia" and "severe "hypercalcemia", "primary hyperparathyroidism", "hypercalcemia of malignancy", "parathyroid hormone measurement", "parathyroidectomy", and "cinacalcet" and through the National Cancer Institute using the term "hypercalcaemia". We also retrieved personal archived references to identify peer reviewed articles. We gave priority to randomised controlled trials, systematic reviews, meta-analyses, and prospective epidemiological studies. As appropriate we also included observational, retrospective, and non-randomised studies and case reports.
• Link to this article online for CPD/CME credits EDUCATION CLINICAL REVIEW Finally, increased serum calcium levels may be observed after kidney transplantation.
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Immobilisation hypercalcaemia-this arises from suppression of bone formation and increased bone resorption, with consequent loss of calcium from the skeleton and hypercalcaemia.
Malignancy related hypercalcaemia
The occurrence of hypercalcaemia together with systemic symptoms (for example, fever, weight loss, decreased appetite, worsening malaise) or rapid onset hypercalcaemia, typically with very high serum calcium levels, should raise suspicion of malignancy. Suppressed or undetectable serum parathyroid hormone levels are found in the setting of hypercalcaemia of malignancy. Hypercalcaemia is usually a late finding in malignancy and is a negative prognostic factor. High serum calcitriol levels are typically associated with lymphoproliferative and granulomatous disorders (see table on thebmj.com). In this context, diagnoses should be considered even in the setting of normal serum calcitriol levels when parathyroid hormone and parathyroid hormone related protein levels are suppressed. The production of the active form of vitamin D is no longer subject to regulation by parathyroid hormone or parathyroid hormone related protein, but rather primarily driven in these conditions by the underlying disease.
Parathyrotoxic crisis
Although acute and severe hypercalcaemia is mostly associated with malignancy, the measurement of parathyroid hormone levels has a key role in excluding parathyrotoxic crisis. Patients require admission to hospital. Parathyrotoxic crisis comprises profound volume depletion, coma, heart failure, and abdominal pain possibly mimicking acute abdomen.
Hyperthyroid activity can be associated with hypercalcaemia and suppressed parathyroid hormone serum levels.
Hypercalcaemia associated with suppressed parathyroid hormone, normal parathyroid hormone related protein, and high or normal serum calcitriol levels strongly suggest the diagnosis of calcitriol mediated diseases (box). Levels of calcidiol should also be checked, particularly in those whose clinical presentation does not suggest the presence of malignancy. Clinical case reports suggest that the occurrence of vitamin D toxicity, although unusual, should be excluded, particularly when the consumption of high doses of exogenous vitamin D is unrecognised.
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Thiazide diuretics
In patients who were hypercalcaemic while taking thiazide diuretics, serum calcium and parathyroid hormone levels should be re-evaluated at least three weeks after withdrawal of the drugs.
How should hypercalcaemia be investigated in primary care?
The primary goal in the differential diagnosis of hypercalcaemia is to determine the underlying mechanism.
Clinicians need to evaluate carefully the severity of clinical presentation, degree of hypercalcaemia, and timing of development of the condition. The table describes the clinical presentation of people with hypercalcaemia. mechanism in the development of hypercalcaemia associated with some forms of malignancy and with granulomatous diseases (box). Malignant cells and granulomas can over-express 1-α-hydroxylase and increase the conversion of calcidiol to the active form of vitamin D, calcitriol, leading to increased intestinal absorption of calcium, hypercalciuria, and hypercalcaemia. Finally, authentic ectopic hyperparathyroidism is a rare cause of hypercalcaemia, with few cases described in the l iterature.
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Thiazide diuretics-thiazides can increase renal re absorption of calcium, resulting in hypocalciuria and eventually high serum calcium levels. As many as 8% of people develop hypercalcaemia while taking thiazides.
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Endocrine disorders-hypercalcaemia is relatively common in people with hyperthyroidism.
10 Hypercalcaemia can be sustained by primary hyperparathyroidism in patients with pheochromocytoma in the setting of multiple endocrine neoplasia type 2. Some pheochromocytomas have been found to secrete parathyroid hormone related protein or to directly stimulate bone resorption.
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Acute renal failure and rhabdomyolysis-patients with rhabdomyolysis associated acute renal failure may develop hypercalcaemia. The use of calcium, calcitriol, or vitamin D analogues supplementation in patients who have end stage renal disease or receive dialysis may cause hypercalcaemia; in this setting, hypercalcaemia may also occur in association with tertiary hyperparathyroidism. EDUCATION CLINICAL REVIEW p rimary hyperparathyroidism. Adults aged 50 or more with primary hyperparathyroidism, a serum calcium level less than 0.25 mmol/L above the upper limit of normal, and without end organ damage may be followed up conservatively. People with serum calcium levels greater than 0.25 mmol/L above the normal range, even if a symptomatic, should be referred for surgery. In addition, regardless of calcium levels, the most recent guidelines for asymptomatic people with primary hyperparathyroidism suggest a more complete evaluation of skeletal and renal complications, including imaging studies.
23 24 Skeletal (osteoporosis, as evaluated by bone mineral density measurement, fragility fractures) or renal involvement (nephrolithiasis or nephrocalcinosis, creatinine clearance <60 mL/min, or hypercalciuria >10 mmol/d associated with an increased risk of stone disease) and age less than 50 years are considered criteria for surgery in people with primary hyperparathyroidism, even when calcium levels are not greater than 0.25 mmol/L above the normal range. 23 In those who decline surgery or are not suitable candidates for surgery, serum calcium and creatinine levels should be measured every year and bone density measured every one or two years, together with monitoring by renal imaging. During follow-up, if the increase in serum calcium levels is greater than 0.25 mmol/L or there is renal or skeletal involvement the patient should be referred for surgery.
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If surgery is not performed, or not indicated, patients should be encouraged to have an above average intake of fluids and avoid drugs, such as thiazide diuretics, that can increase plasma calcium levels. 24 Recently, cinacalcet, a calcimimetic agent, has been proved in a prospective observational study to be effective in lowering serum calcium levels in people with sporadic and familial primary hyperparathyroidism, but it has no effects on other features of primary hyperparathyroidismthat is, bone mineral density and hypercalciuria. 25 The European Medicines Agency in 2008 and the US Food and Drug Administration in 2011 approved the use of cinacalcet in people with primary hyperparathyroidism with specific indications. The EMA panel stated that cinacalcet can be an option in those where parathyroidectomy is indicated based on serum calcium levels but for whom surgery is otherwise "not clinically appropriate or contraindicated." The FDA approves the use of cinacalcet in primary hyperparathyroidism for people with severe hypercalcaemia who are unable to undergo parathyroidectomy.
Severe hypercalcaemia
If serum calcium levels are moderately increased (3.0-3.5 mmol/L), the type of treatment and timing for administering drugs should be guided by clinical manifestations. Admission to hospital is required for people with severe hypercalcaemia (>3.5 mmol/L); emergency treatment includes aggressive intravenous hydration. Hydration alone may be effective in slowly reducing serum calcium levels; however, most commonly it is not the only treatment and may lead to fluid overload. Caution is therefore needed to avoid excessive fluid loading in patients with cardiac and renal disease. In such patients, it is important to assess serum electrolytes and to carry out electrocardiography during treatment.
Loop diuretics, such as furosemide (frusemide), which could theoretically enhance calcium excretion, may Importantly, symptoms associated with chronic hypercalcaemia are related to severe forms-those with chronic mild hypercalcaemia are typically asymptomatic.
Contrary to what is observed among inpatients, hypercalcaemia is most commonly attributable to p rimary hyperparathyroidism in the outpatient setting. In this context the finding of pre-existing mild hypercalcaemia may suggest the diagnosis of primary hyperparathyroidism. However, the detection of mildly increased serum calcium levels on a routine biochemical panel in asymptomatic people is also a common finding.
The evaluation of "outpatients" with hypercalcaemia usually follows a stepwise diagnostic approach (figure). Laboratory evaluation should first include the confirmation of hypercalcaemia by remeasuring serum calcium levels and correcting for albumin or by measuring serum ionised calcium wherever available. Renal function should also be evaluated. Second or third generation immunoradiometric parathyroid hormone assays should be used, as they have been proved to perform similarly and b etter than first generation assays 15 16 ; with a sensitivity in diagnosis of primary hyperparathyroidism ranging from 88% to 97%. Hence, confirmation of hypercalcaemia in association with an increased or non-suppressed or normal parathyroid hormone concentration suggests primary hyperparathyroidism as the most likely diagnosis.
Assessment of vitamin D status is indicated, as low serum calcidiol (25(OH)D) levels are highly prevalent in people with primary hyperparathyroidism. 16 Most recent guidelines suggest a cautious replenishment with supplemental doses of vitamin D in case of hypovitaminosis.
17 Serum levels between 50 and 75 nmol/L are considered the goal of treatment in these patients.
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The diagnosis of primary hyperparathyroidism should be confirmed by ruling out familial hypocalciuric hypercalcaemia, another possible cause of high serum calcium associated with high or unsuppressed serum parathyroid hormone (box). A 24 hour urine collection for calcium and creatinine determination should therefore be performed to calculate the calcium to creatinine clearance ratio. As calcium excretion could possibly be decreased in association with vitamin D deficiency, the accuracy of this evaluation implies the need for replenishment in deficient patients. Calcium to creatinine clearance values less than 0.01 are strongly indicative of familial hypocalciuric hypercalcaemia and require an evaluation of family history of hypercalcaemia and eventually screening of serum calcium in family members. Serum magnesium could be helpful in pointing towards the differential diagnosis of familial hypocalciuric hypercalcaemia, as it is typically in the high range of normal or modestly increased in this condition. Genetic testing is useful for confirmation of the diagnosis.
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How is hypercalcaemia treated? Regardless of the diagnosis, all patients with hypercalcaemia require hydration. The timing and regimens of hydration strongly depend on the severity of the hypercalcaemia. 
Mild hypercalcaemia
EDUCATION CLINICAL REVIEW
Although bisphosphonates are proved to be effective in the treatment of hypercalcaemia, a drug with a rapid hypocalcaemic effect, such as calcitonin, could be used when a prompt resolution is needed. Calcitonin inhibits bone resorption and also decreases renal tubular reabsorption of calcium. Its onset of action is within two hours of being administered, but the effect is short, and drug tolerance commonly develops within two days. Thus, calcitonin is used as an early treatment for severe hypercalcaemia until the onset of the hypocalcaemic effects of other drugs.
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Haemodialysis (as well as peritoneal dialysis) against a low or zero calcium dialysate is a treatment option in cases of treatment failure or when calcium levels are so high as to be life threatening.
It should be borne in mind that in hypercalcaemia of malignancy treatment of the underlying malignancy will also reduce serum calcium levels. Surgical removal of the lesion is currently the only cure for severe hypercalcaemic crisis associated with parathyroid carcinoma, an extremely rare presentation requiring urgent admission to hospital.
Different treatments need to be considered in people with hypercalcaemia from other causes, such as vitamin D intoxication or granulomatous disorders. Since in these cases, the underlying cause is an increased production of calcidiol, drugs that enhance vitamin D metabolism, such as glucocorticoids, are indicated.
worsen electrolyte derangements and volume depletion when administered at high doses. Thus, even in patients with volume overload, loop diuretics should be used with caution. A recent review of randomised controlled trials, prospective single group trials, systematic reviews, and meta-analyses shows limited or no evidence to support the use of loop diuretics in people with hypercalcaemia.
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Since the major mechanism responsible for severe hypercalcaemia is the increased bone resorption from activation of osteoclasts, bisphosphonates are the treatment of choice as they inhibit the osteoclast's' activity. Pamidronate and zoledronic acid are approved by EMA and FDA for the treatment of hypercalcaemia of malignancy, both having shown effectiveness in clinical trials.
28 29 Head to head comparison of pamidronate and zoledronic acid in two randomised controlled trials showed that zoledronic acid was superior to pamidronate in both efficacy and duration of response. 30 The most common reported side effects have been transient fever, myalgias, and infusion site reaction. Zoledronic acid is contraindicated in patients with creatinine clearance values lower than 30 mL/min; in this situation, dose re duction according to creatinine clearance values could be an option. Ibandronate, a bisphosphonate with lower renal toxicity, is approved by EMA for the treatment of malignancy related hypercalcaemia. ) should be directly measured, whenever available, through the ion specific electrode and could increase accuracy of diagnosis. GFR=glomerular filtration rate
